GlaxoSmithKline says five late-stage trials meet main goal

(Reuters) - GlaxoSmithKline Plc said results from five late-stage trials of two experimental quadrivalent influenza vaccines (QIV) met the main goal of protecting against mild as well as moderate-severe cases of influenza.

GSK said its experimental vaccines contain two influenza A strains and two influenza B strains to potentially help broaden protection against seasonal influenza, compared to approved trivalent vaccines that contain two A influenza strains and one B influenza strain.

(Reporting by Monika Shinghal in Bangalore)